Results 21 to 30 of about 25,148 (309)
Frontiers in Endocrinology, 2022 Patients with Gaucher disease (GD) have progressive bone involvement that clinically presents with debilitating bone pain, structural bone changes, bone marrow infiltration (BMI), Erlenmeyer (EM) flask deformity, and osteoporosis. Pain is referred by the
Margarita M. Ivanova +5 more
doaj +2 more sources
How accurate is your sclerostin measurement?:Comparison between three commercially available sclerostin ELISA kits [PDF]
Calcified Tissue International, 2016 Sclerostin, bone formation antagonist is in the spotlight as a potential biomarker for diseases presenting with associated bone disorders such as chronic kidney disease (CDK-MBD). Accurate measurement of sclerostin is therefore important.
Fisher, Emily +6 more
core +5 more sources
Sclerostin: From Molecule to Clinical Biomarker
International Journal of Molecular Sciences, 2022 Sclerostin, a glycoprotein encoded by the SOST gene, is mainly produced by mature osteocytes and is a critical regulator of bone formation through its inhibitory effect on Wnt signaling.
A. Omran +3 more
semanticscholar +4 more sources
Identification of Sclerostin as a Putative New Myokine Involved in the Muscle-to-Bone Crosstalk
Biomedicines, 2021 Bone and muscle have been recognized as endocrine organs since they produce and secrete “hormone-like factors” that can mutually influence each other and other tissues, giving rise to a “bone–muscle crosstalk”.
Maria Sara Magarò +13 more
doaj +2 more sources
Cardiovascular Safety and Sclerostin Inhibition - a mini-review.
The Journal of Clinical Endocrinology & Metabolism, 2021 Sclerostin is primarily produced by the osteocytes, inhibits the canonical Wnt pathway and thereby the osteoblasts, and stimulates RANKL release by the osteocytes and thereby osteoclast recruitment.
B. Langdahl, L. Hofbauer, J. Forfar
semanticscholar +4 more sources
Association Between Sclerostin and Sarcopenia-Related Functional Decline in Older Women [PDF]
DiagnosticsBackground: Sclerostin, an osteocyte-derived glycoprotein, plays a key role in bone metabolism by inhibiting the Wnt/β-catenin signaling pathway. While it is a recognized therapeutic target in osteoporosis, its relationship with sarcopenia remains ...
Dong Gyu Lee, Jong Ho Lee, Eunjung Kong
doaj +2 more sources
Serum sclerostin levels are positively related to bone mineral density in peritoneal dialysis patients: a cross-sectional study [PDF]
BMC Nephrology, 2019 Background Sclerostin, an antagonist of the Wingless-type mouse mammary tumor virus integration site (Wnt) pathway that regulates bone metabolism, is a potential contributor of chronic kidney disease (CKD)–mineral and bone disorder (MBD), which has ...
Te-Hui Kuo +7 more
doaj +2 more sources
Role of Sclerostin in Cardiovascular Disease
Arteriosclerosis, Thrombosis, and Vascular Biology, 2022 Sclerostin is most recognized for its role in controlling bone formation but is also expressed in the heart, aorta, coronary, and peripheral arteries. This review summarizes research on sclerostin’s role in cardiovascular disease.
J. Golledge, S. Thanigaimani
semanticscholar +4 more sources
Role of sclerostin in mastocytosis bone disease [PDF]
Scientific ReportsMastocytosis is a heterogeneous group of disorders, characterized by accumulation of clonal mast cells which can infiltrate several organs, most often spine (70%). The pathogenesis of mastocytosis bone disease is poorly understood.
Aneta Szudy-Szczyrek +18 more
doaj +2 more sources
Decreased Sclerostin Secretion in Humans and Mice With Nonalcoholic Fatty Liver Disease [PDF]
Frontiers in Endocrinology, 2021 ObjectivesGrowing evidence argues for a relationship between liver and bone metabolisms. Sclerostin is a secreted glycoprotein and could antagonize osteoblast-mediated bone formation.
Fangli Zhou +7 more
doaj +2 more sources